1,2,4-triazoles have been reported to possess a wide range of biological activities, including anticancer, antifungal, antiviral and antibacterial activities. Therefore, the current investigation is intended to synthesize six novel 1,2,4-triazole derivatives (designated as 2aa, 2ab, 2ac, 2bb, 2bd, and 2be). These derivatives were screened for their antibacterial activity against two Gram-negative bacteria isolated from clinical specimens (stool and ear exudates of infected patients) and two Gram-positive standard bacteria (Staphylococcus aureus ATCC29213 and Bacillus cereus ATCC11778) using both well diffusion and broth dilution methods. The chemical structures of the new 1,2,4-triazole derivatives were characterized by 1 H and 13 C-NMR spectra, in addition to elemental analysis. The bacterial strains designated as GN1 and GN2 were identified by biochemical and molecular methods and confirmed as new strains of Shigella sp., and Pseudomonas aeruginosa, respectively. All triazole derivatives were found to be active against bacteria with varying degrees. Some derivatives were found to have the same antibacterial activity as penicillin G (the positive control) against certain strains, for instance, 2ab, 2bd, and 2be against B. cereus ATCC11778. Interestingly, some compounds were more active than penicillin G against certain strains. The activity of 2aa against B. cereus ATCC11778 was higher than the activity of penicillin G, whereas 2ab and 2ac were more active than penicillin G against the clinical isolate P. aeruginosa. The variation seen in antimicrobial activity could be attributed to the difference in the substituent groups attached to the 1,2,4-triazole nucleus. In conclusion, these findings might hold promise for development of a new class of a novel expanded spectrum antibiotics against clinically important bacteria that are highly resistant to current antibacterial agents and associated with serious and life-threatening infections.
Introduction
Infectious diseases caused by highly resistant bacteria are still the leading cause of death in developing countries and among the chief causes of mortality in developed countries. Worldwide, infectious diseases account for 23.5% of 58.7 million annual deaths [1] . Therefore, pathogenic microorganisms, particularly emerging pathogens and drug-and multidrug-resistant pathogens, represent a serious challenging problem in modern medicine. Consequently, more careful use of currently available drugs and discovery of new drugs are needed to overcome the nonstop problem of infectious diseases [2] .
Scientists around the world have begun synthesizing and developing a wide range of synthetic antimicrobial agents by the means of organic chemistry. Sulfonamides, nalidixic acid, and quinolones are just few examples of the early synthetic antimicrobial agents with chemotheraptic applications [3] . Recently,
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triazole compounds such as 1,2,4-triazoles represent an important group of such synthetic antimicrobial compounds that are gaining more interest and access in the field of microbial chemotherapy [4, 5, 6 ].
The name "triazole" was first used by Bladin in 1855 to describe the carbon-nitrogen ring system C 2 H 3 N 3 and its derivatives [5] . Later, several novel triazole compounds were synthesized and the biological activities of some of them were proved. The confirmed biological activities include antibacterial [5, 7] , antifungal [8, 9, 5] , antiviral [10] , anti-inflammatory [11] and antioxidant activities [4] . Fluconazole, itraconazole, and posaconazole are examples of triazole derivatives that are already available in the pharmaceutical market and being used to treat several types of mycoses [5] .
Despite these achievements, many clinically important bacterial isolates still present a real challenge for many physicians, especially among those isolates that are highly resistant to current antibacterial agents and associated with serious and life-threatening infections. As consequence, a combination therapy of two or three antimicrobial agents has been sometimes practiced by physicians, especially in patients infected with highly resistant pathogenic bacteria. However, a great concern to the usage of combination therapy has been recently increased due to risks of side effects of drug reactions and interactions with other drugs administered to those type of patients. Therefore, the need for new class of compounds possessing a broad spectrum of antibacterial activity that are highly effective against those highly resistant Gram positive and negative bacteria is increasing, and it is becoming the top priority of most government heath institutions and the world health organizations.
In the light of these facts, this current study is aimed to synthesize some novel 1,2,4-triazole derivatives with hope that these 1,2,4-triazole derivatives might possess a broad spectrum of antibacterial activity against some bacterial isolates obtained from clinical specimens obtained from infected patients as well as against some well-known bacterial strains from American type culture collection (ATCC).
Materials and Methods
Synthesis of the new 1,2,4-triazole derivatives
The triazole-hydrazide derivatives 1 (Scheme 1) were synthesized from the corresponding esters [12] . These derivatives were used as starting materials for the synthesis of compounds 2, by reaction with the appropriate sulfonyl chloride (4-nitrophenyl-, 2,5-dichlorophenyl-, 4,7-dimethyl-2-oxo-2H-chromene-6-, 2-thiophene-, and 3-trifluoromethyl-benzene sulfonyl chloride) in the presence of pyridine as catalyst in 65-79% yield (Scheme 1). The structures of the newly prepared compounds were confirmed on the basis of their 1 H-and 13 C-NMR spectra in addition to elemental analysis. 
Chemical and analytical methods
Chemical names follow IUPAC nomenclature. Starting high purity materials were purchased from Aldrich, Acros, Lancaster, Merck, or Fluka and were used as received without purification. Melting points were measured on a Mettler FP1 melting point apparatus and are uncorrected. All new compounds were analyzed for C, H, and N, and the observed results agreed with the calculated percentages to within ±0.4%. 1 H and 13 C-NMR spectra were recorded on a Bruker DRX-500 instrument. Chemical shifts are given in parts per million (ppm), and tetramethylsilane (TMS) was used as internal standard for spectra obtained in CDCl 3 . All coupling constants (J) are given in Hertz.
General procedure for synthesis of compounds (2aa-ac, 2bb, 2bd, 2be) Compound 1 ( 0.5 mmol), reacted with substituted carbonyl chlorides (0.6 mmol) in chloroform (20 ml) in the presence of pyridine (5 drops) and stirred for 48 h at room temperature. Then residue was evaporated to dryness and the residue was partitioned between CHCl 3 (40 mL) and water (3 x 40 mL). The organic phase
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was evaporated to dryness (Na 2 SO 4 ). The product was then filtered and washed with diethyl ether to afford compounds 2. Recrystallization from CH 2 Cl 2 / ether. N'[2-(1-ethyl-5-methyl-1H-[1,2,4]triazole -3-yl) acetyl]-hydrazide (2aa) The title compound was prepared from compound 1a (0.092 g, 0.5 mmol), and 4-nitrophenyl sulfonyl chloride (0.133 g, 0.6 mmol) in chloroform (20 ml) according to the procedure described above. 
4-Nitrobenzene sulfonic acid
2-Thiophene sulfonic acid N'[2-(1,5-diethyl-1H-[1,2,4]triazole-3-yl)-acetyl] -hydrazide (2bd)
The title compound was prepared from compound 1b (0.099 g, 0.5 mmol), and 2-thiophene sulfonyl chloride (0.110 g, 0.6 mmol) in chloroform (20 ml) according to the procedure described above. 
3-Trifluoromethyl-benzene sulfonic acid N'[2-(1,5-diethyl-1H-[1,2,4]triazole -3-yl)-acetyl] -hydrazide (2be)
The title compound was prepared from compound 1b (0.099 g, 0.5 mmol), and 3-trifluoromethyl-benzenesulfonyl chloride (0.174 g, 0.6 mmol) in chloroform (20 ml) according to the procedure described above. 
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Antibacterial activity testing
Bacterial strains
The bacterial strains used in this study originate from two sources: ATCC and medical samples. ATCC strains include two Gram-positive bacteria Staphylococcus aureus ATCC29213 and Bacillus cereus ATCC11778. Those standard strains were kindly offered by Dr. Emad Malkawi from the department of biological sciences at Yarmouk University, Jordan. The medical strains were isolated from the stool and the ear exudates of infected persons. Isolates were obtained from the clinical microbiology laboratories at Al-Mafraq hospital in Al-Mafraq city, Jordan. These two bacterial strains were designated as GN1 and GN2. The two isolates were first identified by Gram staining and they were then subjected to further identification using the biochemical and molecular methods.
Briefly, isolated bacteria were tested for oxidase [13] . Oxidase test is a prerequisite to conduct the biochemical identification using RapID ONE system and ERIC software (Remel, USA) which were used to identify the isolated Gram-negative, oxidase-negative strains to the species level. GN1 strain was identified by the aforementioned method, while GN2 could not be identified by the previously mentioned approach due to positive oxidase test. Therefore, the GN2 strain was identified by the molecular methods, namely, 16S rDNA sequencing and analysis. In this method, DNA was extracted from the isolate and subjected for 16S rDNA sequencing as previously described [14] . 16S rDNA sequencing was carried out by Macrogen sequencing facility (MacrogenInc, Seoul, South Korea) following the procedure mentioned previously by Jacob and Irshaid, 2012 [14] . The resulting nucleotide sequences were then analyzed by the Basic Local Alignment Search Tool (BLAST) search to identify the closest relatives of our strains.
Agar well diffusion and broth dilution methods
Ten milligrams of each newly synthesized triazole derivative were dissolved in 1 mL of dimethyl sulfoxide (DMSO). DMSO was used as negative control, whereas penicillin G (10 mg mL -1 ) was used as a positive control. All test chemicals and controls were stored in dark at room temperature until use.
Antibacterial activity of the new compounds was first evaluated by well diffusion method [15] . Briefly, Mueller-Hinton agar (MHA) medium was used to prepare MHA agar plates. MHA plates were inoculated with the tested bacterium. Six millimeter holes were punched in the MHA plates. Then, each well was filled with 50 μL of one of each synthesized triazole (10 mg mL -1 ). Penicillin G (10 mg mL -1 ) was used as positive control and DMSO was used as negative control. After incubation, the average diameter of inhibition zone around each well was measured to the nearest millimeter. Each experiment was done in triplicate. To determine the MIC values of each active compound, mixtures of nutrient broth, inoculums, and test compounds were prepared in a microwell plate to yield the following final concentrations: 3000, 2000, 1000, 500, and 250 µg mL -1 .
Penicillin G and DMSO were used as positive control and negative control, respectively. The MIC value is the lowest dilution of the test compound which inhibit the growth judged by lack of turbidity in the well. Each experiment was done in triplicate.
Results
Synthesis and identification of the new 1,2,4-triazole derivatives
Six new 1,2,4-triazole derivatives have been synthesized using substituted carbonyl chlorides in chloroform in the presence of pyridine and stirred for 48 h at room temperature. These six 1,2,4-triazole compounds differ in their side group substituent's on the triazole ring. The structures of these six 1,2,4-triazole compounds were confirmed by 1 H-NMR, 13 C-NMR, and elemental analysis ( Figure 1) . Then, these compounds were investigated for their potential antibacterial activity. 
Isolation and identification of new medical bacterial strains
Two new bacterial strains were collected from the stool and the ear exudates of infected human. These two strains were isolated and identified by biochemical and molecular methods and used in this study. These isolates were assigned as GN1 and GN2. GN1 are characterized by being Gram-negative and oxidase-negative. GN1 was further identified based on biochemical analysis as Shigella sp. The other main biochemical properties of strain GN1 are shown in Table 1 . On the other hand, strains GN2 was identified only after sequencing the 16S rDNA. The 16S rDNA sequence of the newly isolated strains GN2 is shown in Figure 2 . The closest relatives of the isolated strains is Pseudomonas aeruginosa with 99% identity according to BLAST search. 
Antibacterial activity of the new 1,2,4-traizole derivatives
The new 1,2,4-traizole derivatives (2aa, 2ab, 2ac, 2bb, 2bd, and 2be) were tested for their antibacterial activity by two methods: agar well diffusion method and broth dilution method. Figure 3 shows the results obtained from agar well diffusion method. As shown in the figure, the compound 2aa was active against two strains: Shigella sp., and B. cereus. The highest activity was observed against B. cereus (Inhibition zone: 15 mm). Additionally, 2ab was active against three strains. The susceptible strains are: P. aeruginosa, S. aureus, and B. cereus. Shigella sp. was resistant to this compound. It was also found that 2ac is active Test  URE  ADH  ODS  LDC  TET  LIP  KSF  SBL  GUR  ONPG  BGLU  BXYL  NAG  MAL  PRO  GGT  PYR (Figure 3 ).
The activity of penicillin G (the positive control) against the test strains is also shown in Figure 3 Regarding the MIC values of the active compounds, it was found that the MIC value of 2aa compound against the sensitive strains B. cereus and P. aeruginosa is 750 µg mL -1 (Figure 4) . The highest MIC value of this compound was 1250 µg mL -1 against Shigella sp. 2ab was active against P. aeruginosa and B. cereus with MIC value of 500 µg mL -1 , and the compound has lower activity against S. aureus with higher MIC value (2000 µg mL -1 ) (Figure 4) . The MIC values of 2ac compound against the sensitive strains were also determined. MIC value of the compound against the clinical isolate P. aeruginosa was found to be 750 µg mL -1 . The MIC value against B. cereus was 1000 µg mL -1 . The MIC value against Shigella sp. was 1000 µg mL -1 . The MIC value of 2bb against B. cereus was also Some compounds were found to have the same antibacterial activity of penicillin G against certain strains. For instance, 2ab, 2bd, and 2be created the same inhibition zone as penicillin G against B. cereus (Inhibition zone of 10 mm). Interestingly, some compounds were more active than penicillin G against certain strains. For instance, the activity of 2aa against B. cereus was higher than the activity of penicillin G (Figure 2) . Also, 2ab, 2ac, and 2bd were more active than penicillin G when tested against the clinical isolate P. aeruginosa (Figure 2) . The inhibition zones of 2ab was 13 mm, and in case of 2ac was 16 mm, and in case of 2bd was 15 mm. However, no inhibition zone was detected in case of penicillin G was against P. aeruginosa.
Discussion
The presence of highly resistant pathogenic bacteria that are resistant to commercial available antibacterial agents led scientists to look for more potent or effective antibacterial agents. Therefore, this study was undertaking to synthesize six 1,2,4-triazole compounds with hope that these derivatives may exhibit potent antibacterial activity against some bacterial isolates obtained from clinical specimens and some bacterial strains obtained from American type culture collection.
In this study, six 1,2,4-triazole derivatives were newly synthesized and tested for their antibacterial activity against different Gram-positive and Gram-negative bacterial strains. The bacterial strains used in this study include standard bacterial strains as well as clinical bacterial strains. Bacteria from clinical samples were newly isolated from stool and ear exudate of infected persons. They were identified using biochemical and molecular identification techniques, and their susceptibility to the new 1,2,4-triazole derivatives were then evaluated.
Two different types of bacterial strains (i.e., standard and clinical strains) were included in this study to include pathogenic bacteria of medical importance. The first medical bacterial isolate represents a new strain in the genus Shigella. Shigella sp. is the etiologic agent of human shigellosis [16] . It has been estimated that Shigella sp. can causes about 90 million cases of serious dysentery with at least 100 thousands of these resulting in death each year, particularly among children in the developing world [17] .
The second medical isolate represents a new strain of P. aeruginosa which is an opportunistic bacterium that can cause serious infections in human [18] . P. aeruginosa is a well known as opportunistic pathogen of human being that can cause a variety of infections, including urinary tract infections, respiratory system infections, gastrointestinal infections, bacteremia, and other systemic infections [19, 20] . P. aeruginosa infection can be very serious or sometimes life threatening to human, particularly in patients with severe burns, cancer, cystic fibrosis, AIDS as well as immunosuppressed patients.
Interestingly, P. aeruginosa was already resistant to pencillin G (the positive control) but sensitive to three of the newly synthesized triazole compounds (compounds 2ab, 2ac, and 2bd). In facts, numerous epidemiological studies reported that antibiotic resistance is increasing among various bacterial species especially in clinical isolates. This justifies the need to include newly isolated clinical bacterial strains in addition to standards strains. The failure of known antibiotics to control pathogens can be attributed to several factors. For instance, the emergence of novel pathogens in human populations [21] , re-emergence of pathogens [22] , acquisition of new virulence traits as a result of adaptation to new hosts or acquisition of plasmids, conjugative transposons and integrons containing various resistance genes [22] .
Previous studies showed that 1,2,4-triazole derivatives are important group in the field of medicinal chemistry due to their diverse biological properties [23] . The biological activity of triazoles is highly dependent on the chemical side groups that may enhance their activity. In this study, six 1,2,4-traizole derivatives were newly synthesized: 2aa, 2ab, 2ac, 2bb, 2bd, and 2be. These compound differ in their side groups. In the next section, we will further discuss the effect of side groups on triazole activity.
The 2aa compound has a nitrobenzene sulfonic acid as substituent group ( Figure  1 ). 2aa showed antibacterial activity against one Gram negative bacteria (Shigella sp.) and one Gram positive bacterium (B. cereus). Presence of nitrobenzene in triazoles seem to enhance the antibacterial activity of trizaoles as documented in previous studies [24] .
The 2ab compound was almost the broadest in its activity spectrum. It was active against three bacterial strains out of four, and it was more active than pencillin G in case of P. aeruginosa. 2ab contains dichlorobenzene sulfonic acid. Presence of chlorine in the structure is the most distinguished feature when comparing 2ab to 2aa. Presence of chlorine is expected to enhance the antibacterial activity because due to its moderately oxidative effect and can react with various components of the bacterial cell [25] .
The distinguished substituent group in compound 2ac is chromene which is a polycyclic organic structure that results from fusion of a benzene ring to a heterocyclic pyran ring. Previous studies showed that heterocyclic compounds containing chromene have an antimicrobial activity against both Gram positive and negative bacteria [26] . This conclusion agrees with our results which showed that the compound 2ac was active against two Gram negative bacteria, namely, Shigella sp. and P. aeruginosa, as well as one Gram positive bacterium, B. cereus. 2bb contains a dichlorobenzene sulfonic acid as in 2ab. However, contrary to 2ab which contains two ethyl group bonded to triazole ring, 2bb contains one methyl and one ethyl group attached to triazole ring. Presence of ethyl group instead of methyl group dramatically decreases the antibacterial activity of the triazole compound when 2bb and 2ab are compared. 2be contains triflouromethyl benzene. The distinguished feature in 2be is the presence of fluoride. The inhibitory effect of fluoride on bacteria is well established [27] . Fluoride can inhibit the metabolism of bacteria through different mechanisms like enzyme inhibitor or increases the acid sensitivity of bacteria [27] .
In conclusion, the 2aa triazole derivative was more active than penicillin G when tested against B. cereus, and 2ab and 2ac triazole compounds were also more active than penicillin G when tested against P. aeruginosa. Thus, it is possible to anticipate that these novel triazole compounds are highly efficient against most clinically important species of Gram negative and positive bacteria that are highly resistant to current antibacterial agents and associated with serious and life-threatening infections. These findings might hold promise for development of a new class of a novel expanded spectrum antibiotic particularly from 2aa, 2ab and 2ac triazole compounds. It is also possible to suggest that these three triazole compounds appear to be good candidates for further clinical investigations in vivo. Therefore, we recommend that clinical trials might be carried out to evaluate the possibility of using them as an alternative to penicillin G for the treatment of infections caused by these two microorganisms as well as other bacterial species. In addition, their pharmacodynamic and pharmacokinetic properties must also be studied.
